• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-26

  Phosbind Acrylamide adds an antibody-independent mobility readout to protein phosphorylation analysis, helping distinguish altered phosphorylation from altered protein abundance. This workflow applies especially well to Kv6.1–Kv2.1 variant studies, kinase assays, and signaling experiments involving targets from 30–130 kDa.

• Dasatinib: From Kinase Target to Cancer Phenotype

  2026-08-26

  Dasatinib (BMS-354825) can connect kinase inhibition with measurable cancer phenotypes across leukemia, prostate, and PDAC models. This guide uses the SNAI1–PIK3R2/p-EphA2 study to show how pathway, cell-state, and microenvironment assays can be interpreted without conflating mechanistic evidence.

• Diuron-Induced Acute Renal Injury and JAK2/STAT1

  2026-08-25

  The 2025 reference study integrates network toxicology, molecular docking, transcriptomic analysis, and HK-2 cell experiments to examine how Diuron may promote acute kidney injury. Its results identify JAK2/STAT1 signaling as a central mechanistic hypothesis and provide a framework for connecting computational toxicology with experimentally testable renal endpoints.

• H. pylori, p38, and IL-8 in Pediatric Airways

  2026-08-25

  The reference study shows that Helicobacter pylori stimulates IL-8 production in pediatric airway epithelial cultures through its cag type IV secretion system and p38 MAP kinase, rather than primarily through NOD1 or NF-κB. Its age-stratified primary-cell model provides a useful framework for distinguishing pathogen-specific signaling from general inflammatory responses.

• Cholesterol in Translational Membrane Assays

  2026-08-24

  Cholesterol is the principal sterol linking membrane biophysics, lipid metabolism research, and formulation quality control. This article uses the recent localized p21 mRNA–LNP bladder cancer study to define what cholesterol-based assays can reveal—and what they cannot prove about therapeutic nanoparticles.

• Ciprofloxacin Workflows for Resistance and Nanomedicine

  2026-08-24

  This practical guide positions Ciprofloxacin as both a mechanistic probe for bacterial DNA replication inhibition and a controlled payload for emerging nanotheranostic assays. It combines antimicrobial resistance research workflows with the ultrasound-activated ZIF8 platform reported for triple-negative breast cancer, emphasizing solvent control, assay comparators, and troubleshooting.

• Methicillin Sodium Salt: Designing Better Assays

  2026-08-23

  Methicillin sodium salt is more than an MSSA selection agent: it is a mechanistic probe for separating target engagement, phenotype, and resistance genotype. This guide connects PBP biology with disciplined MIC workflows and extracts assay-design lessons from the EAGLE-2 and EAGLE-3 clinical trials.

• Lanabecestat (AZD3293) BACE1 Research Workflow

  2026-08-22

  Build a practical Lanabecestat workflow that connects amyloid-beta production inhibition with synaptic-function measurements. This guide emphasizes exposure titration, paired biochemical and optical assays, and troubleshooting grounded in the finding that moderate BACE1 inhibition can reduce Aβ without necessarily disrupting synaptic transmission.

• GSK3 Inhibition as Host-Directed TB Therapy

  2026-08-22

  The 2024 iScience study identifies glycogen synthase kinase 3 inhibition as a host-directed strategy for restricting intracellular Mycobacterium tuberculosis growth. By combining chemical screening, genetic perturbation, macrophage infection models, and phospho-proteomics, the work connects GSK3 signaling with pathogen-driven macrophage dysfunction and apoptosis.

• U 46619: TP Receptor Agonist Guide

  2026-08-21

  U 46619, also called 11,9 epoxymethano-prostaglandin H2, is a synthetic TP-receptor agonist used to model platelet activation and vascular responses. Product-reported EC50 values distinguish early platelet shape change and myosin light-chain phosphorylation from later serotonin release, aggregation, and fibrinogen-receptor binding.

• Digoxin Workflows for Cardiac and Viral Research

  2026-08-20

  Digoxin supports two distinct research programs: Na+/K+ ATPase-driven cardiac contractility modulation and cell-selective inhibition of chikungunya virus infection. This practical guide connects model selection, dosing, controls, and troubleshooting while separating product-backed findings from workflow recommendations.

• Bromodomain Inhibitor (+)-JQ1: BET Workflows

  2026-08-20

  Bromodomain Inhibitor, (+)-JQ1 converts BET biology into practical workflows for apoptosis, chromatin, cancer combination, inflammation, and reproductive studies. This guide links BRD4-focused mechanism with assay design, dosing controls, and troubleshooting strategies that improve reproducibility.

• CHI3L1-IN-5: CNS Neuroinflammation Workflows

  2026-08-19

  CHI3L1-IN-5 (Compound Z17) enables a paired workflow: measure CHI3L1-mediated NF-κB suppression while testing astrocyte Aβ uptake and lysosomal recovery. Its CNS-oriented physicochemical profile makes it useful for mechanism-led neuroinflammation studies, provided exposure, vehicle, and functional rescue are interpreted separately.

• PX-478 and Prenatal Hypoxia-Induced ASD-Like Behavior

  2026-08-19

  A 2024 rat study examined whether PX-478-mediated HIF-1α inhibition could reduce autism-like behavioral and hippocampal abnormalities after prenatal hypoxia. The findings connect improved behavior with reduced hippocampal HIF-1α, increased PTEN, lower circulating VEGF, and treatment-timing-dependent safety signals.

• T0070907: Practical PPARγ Antagonist Guide

  2026-08-18

  T0070907 is a nanomolar PPARγ antagonist for separating receptor-dependent transcription from downstream phenotypes in adipogenesis, inflammatory macrophage, and cancer models. This guide translates its covalent mechanism into practical workflows, controls, and troubleshooting strategies for reproducible pathway studies.

7837 records 1/523 page Next 12345 下5页 Last page